INDUSTRY INSIGHTS YOUR PEERS ARE READING
Insights on Pharmaceuticals & Medical ProductsMedical affairs is poised for a broader, more strategic role. However, leaders will need to ramp up new types of capabilities and talent to achieve this ambition. MORE
Insights on Pharmaceuticals & Medical ProductsThe president and CEO of JSR Corporation discusses the company’s plans to grow a global healthcare franchise building from his lessons in the semiconductor industry. MORE
The business model of research-based pharmaceutical companies is under significant pressure. However, it also reflects stronger pressures to lower medicine costs in traditional pharmaceutical markets. citizens than pharmaceuticals (the sector’s worst showing in 16 years). And it is the first topic of the provisional standard for the pharmaceutical sector produced by the Sustainability Accounting Standards Board. MORE
And although the pharmaceutical and healthcare industries know this is the way forward, they face some significant hurdles Precision medicine combines business opportunities with clinical health benefits. MORE
Insights on Pharmaceuticals & Medical ProductsFive facts showing that companies should invest in digital customer engagement in Japan. MORE
Regeneratives are pharmaceutical cell therapy products that replace or restore cells and tissues lost to disease or aging. “To be able to do that, they need to entice companies to come to Japan, and they need to entice their own pharmaceutical companies to license in and obtain the best.” It includes a designation system that promotes R&D in Japan aimed at early practical application for innovative pharmaceutical products, medical devices, and regenerative medicines. MORE
Insights on Pharmaceuticals & Medical ProductsMany pharma and medtech companies have a digital strategy. But to pull off a true digital transformation, it's crucial to focus on culture and mindset, according to leaders who attended a recent European roundtable. MORE
Insights on Pharmaceuticals & Medical ProductsWhile there is general agreement that real-world evidence could significantly improve how healthcare stakeholders make decisions, expanding its use requires action by multiple stakeholders. MORE
Insights on Pharmaceuticals & Medical ProductsAs the prevalence and severity of cancer has increased, the drug landscape has shifted. Oncology launches are increasingly critical and require a dedicated approach. Here’s what it entails. MORE
Insights on Pharmaceuticals & Medical ProductsDesign can help craft a standout patient experience. Here, three leaders discuss how the discipline is improving medical products and driving innovation. MORE
Insights on Pharmaceuticals & Medical ProductsThe president of Merck in Japan discusses how healthcare players in the country can capitalize on early detection rates and use collaboration to drive innovation. MORE
The CEO of Eli Lilly offers perspectives on accelerating change in the industry. Our Insights MORE
Insights on Pharmaceuticals & Medical ProductsTwo Merck Healthcare digital specialists explain their company’s transformation and the impact it has had on patients. MORE
The 1984 Drug Price Competition and Patent Term Restoration Act gave pharmaceutical companies exclusive protections for innovating a new drug. ” By selling a drug they’re already making under a different name, pharmaceutical firms are effectively extending their monopoly for another six months. Another way pharmaceutical firms are thwarting generics is by restricting access to samples for testing. Regulation Branding Manufacturing Pharmaceuticals Digital Article MORE
Insights on Pharmaceuticals & Medical ProductsIn increasingly crowded drug markets, a strong clinical profile is no longer enough to ensure a distinctive launch. To be successful, pharma companies need to launch not only products but also experiences. MORE
Organizational culture Gender Policy Corporate governance Healthcare Pharmaceuticals Digital ArticleCarmen Martínez Torrón/Getty Images. MORE
Insights on Pharmaceuticals & Medical ProductsJaak Peeters, head of global public health at Johnson & Johnson, discusses the role pharma can play in addressing big challenges, such as fighting diseases like HIV and tuberculosis. MORE
Two senior Boehringer Ingelheim executives, Joachim Hasenmaier and Felix Gutsche, discuss the global pharmaceutical company’s deal with Sanofi to acquire its animal health business. MORE
Originally, it was catering to pharmaceutical trials … Continue reading → Learning Entrepreneur If you don’t know this company, clearly you are not paying attention. Theranos is a biotechnology start up merging biological systems with information systems. Home healthcare monitoring systems to monitor disease progression in real-time. MORE
Insights on Pharmaceuticals & Medical ProductsIn a sector undergoing unprecedented change, five muscles will define the successful leaders of the future. MORE
Insights on Pharmaceuticals & Medical ProductsEsteban Santos, executive vice president for operations at Amgen, explains how the company is using operations to support innovation. MORE
For 78-year-old Tony, 3,4 DAP — which can be obtained at low cost from compounding pharmacies or for free through a compassionate-use program supported by a small privately held company, Jacobus Pharmaceuticals — is a lifesaver. MORE
Insights on Pharmaceuticals & Medical ProductsThe potential for real-world evidence is expanding, particularly in oncology drug development. To compete, some companies are investing in robust real-world data and analytic capabilities. MORE
Data and digitization are creating a growing array of value-creation choices in industries as diverse as pharmaceuticals, mining, and energy. Digital Insights MORE
Insights on Pharmaceuticals & Medical ProductsUnderstanding structural shifts in the market can help pharma stakeholders innovate and, ultimately, deliver benefits for patients. MORE
A partner of venture-capital firm Atlas Venture, Bruce Booth, explains how investment assists pharmaceutical innovation. Our Insights MORE
We spoke to ten digital leaders at global pharmaceutical companies to understand how they focus their efforts. The life-sciences industry is embracing digital to unlock innovation. Our Insights MORE
Insights on Pharmaceuticals & Medical ProductsFive strategic efforts can help medical affairs teams master customer engagement in the digital age. MORE
That rule of life is no secret to pharmaceutical companies across the globe. Japan remains the world’s second-biggest pharmaceuticals market, behind only the United States and China. The biggest change for pharma in Japan was the 2014 revision of the nation’s keystone pharmaceuticals law, renamed the PMD Act—for pharmaceutical and medical devices. Older people need more medicine. MORE
Insights on Pharmaceuticals & Medical ProductsMedical information teams can be a source of differentiation if used strategically. But the evolving environment means pharma manufacturers will need to make organizational enhancements to get ahead. MORE
Insights on Pharmaceuticals & Medical ProductsJacques Nathan, president of Sanofi Japan, discusses what’s ahead for his changing sector. MORE
1 Pharmaceutical companies are unique in their capacity, due to little regulation and oversight, to raise prices. Pharmaceutical companies focus on a variety of factors when pricing drugs with the main objective of generating the most revenue. Topic: Pharmaceutical Industry in the U.S.” MORE
Insights on Pharmaceuticals & Medical ProductsEnthusiasm for the biopharmaceutical sector in Asia has been flat, due in part to China’s market-access blockade, Japan’s spending controls, and deceleration in India and Southeast Asia. MORE
Insights on Pharmaceuticals & Medical ProductsDesign is increasingly a business imperative, but medtech companies have been slow to embrace it. What benefits might a focus on medical-device design bring, and how can companies get started? MORE
There are lessons for other industries in the way pharma companies use mergers to innovate, work more efficiently, and bolster product portfolios. Strategy & Corporate Finance Insights MORE
Insights on Pharmaceuticals & Medical ProductsAs innovation reshapes the pharma landscape, pharma companies will need to revisit their R&D operating models to thrive. MORE
Insights on Pharmaceuticals & Medical ProductsDigital promises to transform R&D productivity over the next decade. What will it take to realize this potential? MORE
Insights on Pharmaceuticals & Medical ProductsIn the biosimilars market, companies face declining prices and rising competition. What themes will shape the industry in coming months, and how can players set themselves apart? MORE
This is especially true in pharmaceutical markets where new and affordable drugs can improve and even save the lives of many people. Therefore, pharmaceutical mergers seem to substantially reduce innovation activities in the relevant market as a whole. MORE
Innovation Business models Entrepreneurship Healthcare Pharmaceuticals Technology Digital ArticleTEK IMAGE/SCIENCE PHOTO LIBRARY/Getty Images. MORE
Insights on Pharmaceuticals & Medical ProductsHow can medtech companies thrive in the world’s fastest-growing market? MORE
By going digital, biotech pioneers with promising biomolecular platforms are improving drug discovery and development—and changing the pharmaceutical industry. Insights on Pharmaceuticals & Medical Products MORE
Insights on Pharmaceuticals & Medical ProductsAdvanced analysis of genomic data integrated with electronic medical records and other data sets, combined with effective reimbursement strategies and full data-regulatory compliance, will distinguish winning diagnostics companies. MORE
There were about fifteen of us—three from my team and a dozen client personnel—in a conference room at the headquarters of one of the world’s largest pharmaceutical companies. MORE
Pharmaceuticals Related Topics McKinsey
SEPTEMBER 1, 2018
Insights on Pharmaceuticals & Medical ProductsUnderstanding structural shifts in the market can help pharma stakeholders innovate and, ultimately, deliver benefits for patients.
Strategy+Business
FEBRUARY 22, 2018
And although the pharmaceutical and healthcare industries know this is the way forward, they face some significant hurdles Precision medicine combines business opportunities with clinical health benefits.
McKinsey
OCTOBER 11, 2018
There are lessons for other industries in the way pharma companies use mergers to innovate, work more efficiently, and bolster product portfolios. Strategy & Corporate Finance Insights
McKinsey
OCTOBER 27, 2017
The CEO of Eli Lilly offers perspectives on accelerating change in the industry. Our Insights
McKinsey
NOVEMBER 6, 2018
Insights on Pharmaceuticals & Medical ProductsTwo Merck Healthcare digital specialists explain their company’s transformation and the impact it has had on patients.
Harvard Business
MARCH 11, 2018
That rule of life is no secret to pharmaceutical companies across the globe. Japan remains the world’s second-biggest pharmaceuticals market, behind only the United States and China. The biggest change for pharma in Japan was the 2014 revision of the nation’s keystone pharmaceuticals law, renamed the PMD Act—for pharmaceutical and medical devices. Older people need more medicine.
McKinsey
NOVEMBER 9, 2018
Insights on Pharmaceuticals & Medical ProductsHow can medtech companies thrive in the world’s fastest-growing market?
McKinsey
NOVEMBER 1, 2018
Insights on Pharmaceuticals & Medical ProductsAdvanced analysis of genomic data integrated with electronic medical records and other data sets, combined with effective reimbursement strategies and full data-regulatory compliance, will distinguish winning diagnostics companies.
McKinsey
JULY 31, 2018
By going digital, biotech pioneers with promising biomolecular platforms are improving drug discovery and development—and changing the pharmaceutical industry. Insights on Pharmaceuticals & Medical Products
McKinsey
AUGUST 11, 2018
Insights on Pharmaceuticals & Medical ProductsJacques Nathan, president of Sanofi Japan, discusses what’s ahead for his changing sector.
McKinsey
OCTOBER 12, 2018
Insights on Pharmaceuticals & Medical ProductsMany pharma and medtech companies have a digital strategy. But to pull off a true digital transformation, it's crucial to focus on culture and mindset, according to leaders who attended a recent European roundtable.
McKinsey
OCTOBER 6, 2018
Insights on Pharmaceuticals & Medical ProductsAs innovation reshapes the pharma landscape, pharma companies will need to revisit their R&D operating models to thrive.
McKinsey
MARCH 7, 2018
Insights on Pharmaceuticals & Medical ProductsFive facts showing that companies should invest in digital customer engagement in Japan.
McKinsey
NOVEMBER 3, 2018
Insights on Pharmaceuticals & Medical ProductsDigital promises to transform R&D productivity over the next decade. What will it take to realize this potential?
Tom Spencer
JULY 14, 2018
1 Pharmaceutical companies are unique in their capacity, due to little regulation and oversight, to raise prices. Pharmaceutical companies focus on a variety of factors when pricing drugs with the main objective of generating the most revenue. Topic: Pharmaceutical Industry in the U.S.”
McKinsey
JUNE 9, 2018
Insights on Pharmaceuticals & Medical ProductsEsteban Santos, executive vice president for operations at Amgen, explains how the company is using operations to support innovation.
McKinsey
JUNE 13, 2018
Insights on Pharmaceuticals & Medical ProductsJaak Peeters, head of global public health at Johnson & Johnson, discusses the role pharma can play in addressing big challenges, such as fighting diseases like HIV and tuberculosis.
McKinsey
JULY 25, 2018
Insights on Pharmaceuticals & Medical ProductsThe potential for real-world evidence is expanding, particularly in oncology drug development. To compete, some companies are investing in robust real-world data and analytic capabilities.
McKinsey
FEBRUARY 8, 2018
Insights on Pharmaceuticals & Medical ProductsDesign can help craft a standout patient experience. Here, three leaders discuss how the discipline is improving medical products and driving innovation.
McKinsey
MAY 4, 2018
Insights on Pharmaceuticals & Medical ProductsFive strategic efforts can help medical affairs teams master customer engagement in the digital age.
McKinsey
AUGUST 16, 2018
Insights on Pharmaceuticals & Medical ProductsIn increasingly crowded drug markets, a strong clinical profile is no longer enough to ensure a distinctive launch. To be successful, pharma companies need to launch not only products but also experiences.
McKinsey
MAY 16, 2018
Insights on Pharmaceuticals & Medical ProductsEnthusiasm for the biopharmaceutical sector in Asia has been flat, due in part to China’s market-access blockade, Japan’s spending controls, and deceleration in India and Southeast Asia.
McKinsey
JULY 18, 2018
Insights on Pharmaceuticals & Medical ProductsDesign is increasingly a business imperative, but medtech companies have been slow to embrace it. What benefits might a focus on medical-device design bring, and how can companies get started?
McKinsey
JULY 18, 2018
Insights on Pharmaceuticals & Medical ProductsIn the biosimilars market, companies face declining prices and rising competition. What themes will shape the industry in coming months, and how can players set themselves apart?
McKinsey
AUGUST 3, 2018
Insights on Pharmaceuticals & Medical ProductsAs the prevalence and severity of cancer has increased, the drug landscape has shifted. Oncology launches are increasingly critical and require a dedicated approach. Here’s what it entails.
McKinsey
MAY 8, 2018
Insights on Pharmaceuticals & Medical ProductsWhile there is general agreement that real-world evidence could significantly improve how healthcare stakeholders make decisions, expanding its use requires action by multiple stakeholders.
McKinsey
MAY 10, 2018
Insights on Pharmaceuticals & Medical ProductsMedical information teams can be a source of differentiation if used strategically. But the evolving environment means pharma manufacturers will need to make organizational enhancements to get ahead.
McKinsey
APRIL 6, 2018
Insights on Pharmaceuticals & Medical ProductsThe president of Merck in Japan discusses how healthcare players in the country can capitalize on early detection rates and use collaboration to drive innovation.
McKinsey
APRIL 12, 2018
Insights on Pharmaceuticals & Medical ProductsMedical affairs is poised for a broader, more strategic role. However, leaders will need to ramp up new types of capabilities and talent to achieve this ambition.
McKinsey
MARCH 29, 2018
Insights on Pharmaceuticals & Medical ProductsThe president and CEO of JSR Corporation discusses the company’s plans to grow a global healthcare franchise building from his lessons in the semiconductor industry.
Harvard Business
NOVEMBER 12, 2018
Innovation Business models Entrepreneurship Healthcare Pharmaceuticals Technology Digital ArticleTEK IMAGE/SCIENCE PHOTO LIBRARY/Getty Images.
McKinsey
AUGUST 16, 2018
Data and digitization are creating a growing array of value-creation choices in industries as diverse as pharmaceuticals, mining, and energy. Digital Insights
McKinsey
DECEMBER 6, 2016
A partner of venture-capital firm Atlas Venture, Bruce Booth, explains how investment assists pharmaceutical innovation. Our Insights
McKinsey
AUGUST 3, 2018
Two senior Boehringer Ingelheim executives, Joachim Hasenmaier and Felix Gutsche, discuss the global pharmaceutical company’s deal with Sanofi to acquire its animal health business.
Harvard Business
NOVEMBER 1, 2018
Organizational culture Gender Policy Corporate governance Healthcare Pharmaceuticals Digital ArticleCarmen Martínez Torrón/Getty Images.
Harvard Business
JULY 6, 2016
For 78-year-old Tony, 3,4 DAP — which can be obtained at low cost from compounding pharmacies or for free through a compassionate-use program supported by a small privately held company, Jacobus Pharmaceuticals — is a lifesaver.
Harvard Business
FEBRUARY 26, 2018
Regeneratives are pharmaceutical cell therapy products that replace or restore cells and tissues lost to disease or aging. “To be able to do that, they need to entice companies to come to Japan, and they need to entice their own pharmaceutical companies to license in and obtain the best.” It includes a designation system that promotes R&D in Japan aimed at early practical application for innovative pharmaceutical products, medical devices, and regenerative medicines.
David A Fields
AUGUST 24, 2016
There were about fifteen of us—three from my team and a dozen client personnel—in a conference room at the headquarters of one of the world’s largest pharmaceutical companies.
McKinsey
MARCH 10, 2017
We spoke to ten digital leaders at global pharmaceutical companies to understand how they focus their efforts. The life-sciences industry is embracing digital to unlock innovation. Our Insights
Consultants Mind
SEPTEMBER 30, 2014
Originally, it was catering to pharmaceutical trials … Continue reading → Learning Entrepreneur If you don’t know this company, clearly you are not paying attention. Theranos is a biotechnology start up merging biological systems with information systems. Home healthcare monitoring systems to monitor disease progression in real-time.
Harvard Business
APRIL 6, 2017
The 1984 Drug Price Competition and Patent Term Restoration Act gave pharmaceutical companies exclusive protections for innovating a new drug. ” By selling a drug they’re already making under a different name, pharmaceutical firms are effectively extending their monopoly for another six months. Another way pharmaceutical firms are thwarting generics is by restricting access to samples for testing. Regulation Branding Manufacturing Pharmaceuticals Digital Article
Harvard Business
FEBRUARY 3, 2017
The business model of research-based pharmaceutical companies is under significant pressure. However, it also reflects stronger pressures to lower medicine costs in traditional pharmaceutical markets. citizens than pharmaceuticals (the sector’s worst showing in 16 years). And it is the first topic of the provisional standard for the pharmaceutical sector produced by the Sustainability Accounting Standards Board.
Harvard Business
AUGUST 3, 2016
This is especially true in pharmaceutical markets where new and affordable drugs can improve and even save the lives of many people. Therefore, pharmaceutical mergers seem to substantially reduce innovation activities in the relevant market as a whole.
57 
Let's personalize your content